98-29561. Joint Meeting of the Antiviral Drugs Advisory Committee and the Nonprescription Drugs Advisory Committee; Notice of Meeting  

  • [Federal Register Volume 63, Number 214 (Thursday, November 5, 1998)]
    [Notices]
    [Page 59793]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 98-29561]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    
    
    Joint Meeting of the Antiviral Drugs Advisory Committee and the 
    Nonprescription Drugs Advisory Committee; Notice of Meeting
    
    AGENCY: Food and Drug Administration, HHS.
    ACTION: Notice.
    
    -----------------------------------------------------------------------
    
        This notice announces a forthcoming meeting of a public advisory 
    committee of the Food and Drug Administration (FDA). The meeting will 
    be open to the public.
    
        Name of Committee: Antiviral Drugs Advisory Committee and the 
    Nonprescription Drugs Advisory Committee.
        General Function of the Committees: To provide advice and 
    recommendations to the agency on FDA's regulatory issues.
        Date and Time: The meeting will be held on December 1, 1998, 8:30 
    a.m. to 5 p.m.
        Location: Holiday Inn, Versailles Ballrooms I and II, 8120 
    Wisconsin Ave., Bethesda, MD.
        Contact Person: Rhonda W. Stover or Sandra L. Titus, Center for 
    Drug Evaluation and Research (HFD-21), Food and Drug Administration, 
    5600 Fishers Lane, Rockville, MD 20857, (301-827-7001, or FDA Advisory 
    Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
    Washington, DC area), code 12531. Please call the Information Line for 
    up-to-date information on this meeting.
        Agenda: The committees will jointly discuss new drug application 
    (NDA) N20-629, to switch penciclovir (Denavir, SmithKline 
    Beecham) topical cream from prescription status to over-the-counter 
    status for the treatment of recurrent herpes labialis (cold sores) in 
    immunocompetent adults.
        Procedure: Interested persons may present data, information, or 
    views, orally or in writing, on issues pending before the committee. 
    Written submissions may be made to the contact person by November 24, 
    1998. Oral presentations from the public will be scheduled between 
    approximately 1 p.m. and 2 p.m. Time allotted for each presentation may 
    be limited. Those desiring to make formal oral presentations should 
    notify the contact person before November 24, 1998, and submit a brief 
    statement of the general nature of the evidence or arguments they wish 
    to present, the names and addresses of proposed participants, and an 
    indication of the approximate time requested to make their 
    presentation.
        Notice of this meeting is given under the Federal Advisory 
    Committee Act (5 U.S.C. app. 2).
    
        Dated: October 27, 1998.
     Michael A. Friedman,
     Deputy Commissioner for Operations.
    [FR Doc. 98-29561 Filed 11-4-98; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
11/05/1998
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
98-29561
Pages:
59793-59793 (1 pages)
PDF File:
98-29561.pdf